A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients with Type 2 Diabetes Mellitus

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221754

Enrollment

Unknown

Registered

2012-04-02

Start date

2012-04-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

investigational material(s) Generic name etc : LY2189265 INN of investigational material : Dulaglutide Therapeutic category code : 249 Other hormone preparations (including antihormone preparations) D

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Participants who have had a diagnosis of type 2 diabetes mellitus before screening -Participants who have been OAM-naive (diet and exercise only) or been taking OAM monotherapy except for thiazolidinedione (TZD) and are willing to discontinue this medication. Participants taking OAM monotherapy must complete 8-week washout period prior to randomization -Participants who are OAM naive with screening glycosylated hemoglobin (HbA1c) value of 7.0% to 10.0% and randomization HbA1c value of 7.0% to 10.0%, or who are taking OAM monotherapy with screening HbA1c value of 6.5% to 9.0% and randomization HbA1c value of 7.0% to 10.0%. -Participants who have a body mass index (BMI) of 18.5kg/m2 to 35.0kg/m2

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026